Clinical Trial Detail

NCT ID NCT03734016
Title A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications

CLL/SLL

Therapies

Ibrutinib

Zanubrutinib

Age Groups: adult senior

No variant requirements are available.